Clinical efficacy of sacubitril/valsartan in elderly patients with ventricular arrhythmias caused by heart failure
Objective To explore the clinical efficacy of sacubitril/valsartan in the treatment of ventricular arrhythmias caused by heart failure(HF)in elderly patients.Methods A total of 186 elderly HF patients hospitalized in our department from April 2020 to December 2022 were enrolled and then randomly divided into control group(n=93,conventional treatment plan)and observation group(n=93,sarcubatrixartan administration besides conventional treatment).The clinical efficiency and incidence of adverse reactions were compared between the two groups.The following indicators were compared between the two groups before and after treatment,includ-ing electrocardiogram indicators[QRS time limit,corrected QT interval(QTc),QT dispersion(QTd),Sv1+Rv5],cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end diastolic dimension(LVEDD),left ventricular posterior wall thick-ness(LVPWT),6-minute walking test(6MWT),premature ventricular contraction(PVCs),non-sustained ventricular tachycardia(NSVT),sustained ventricular tachycardia(SVT)]and serum indicators[serum creatinine(SCr),blood urea nitrogen(BUN),B-type brain natriuretic peptide(BNP),and cardiac troponin T(cTnT)].SPSS statistics 22.0 was used for data analysis.Student's t test or Chi-square test was employed for intergroup comparison depending on date type.Results The total clinical efficiency rate was significantly higher in observation group than control group(95.70％vs 86.02％,P＜0.05).No statistical difference was observed in incidence of adverse reactions between the two groups(11.83％vs 7.53％,P＞0.05).Before treatment,there were no obvious differences in electrocardiogram,cardiac function and serum indicators between the two groups(P＞0.05).After treatment,the observation group obtained better QRS duration,QTc,QTd,and Sv1+Rv5,notable declines in the proportions of SVT patients and NSVT patients,lower PVCs times and average SVT and NSVT times,great improvements in LVEF,LVEDD and 6MWT,and reduced serum levels of SCr,BUN,BNP and cTnT when compared with the control group(P＜0.05).Conclusion Shakubaqu/valsartan shows significant clinical efficacy in treatment of HF-caused ventricular arrhythmia in elderly patients,with advantages of good safety and reliability,reducing the occurrence of ventricular arrhythmia,and improving heart function,exercise tolerance and myocardial injury.
万方数据
维普
